GlyTherix plans to use 177Lu-DOTAMiltuximab® in its planned Australian Phase Ib in 2025, followed by US Phase II trials in 2026. “GlyTherix is building a global network of radioisotope suppliers to ...
Since the construction of the first commercial light water nuclear power plants (LWR) the design of their fuel rods hasn’t changed significantly. Mechanically robust and corrosion-resistant ...